<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097290</url>
  </required_header>
  <id_info>
    <org_study_id>CAPTIVATE</org_study_id>
    <secondary_id>IDE# G130241</secondary_id>
    <nct_id>NCT02097290</nct_id>
  </id_info>
  <brief_title>Evaluation of Automatic Threshold Algorithms</brief_title>
  <acronym>CAPTIVATE</acronym>
  <official_title>CAPTure Information Via Automatic Threshold Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the PaceSafe Right Ventricular Autothreshold (RVAT) and Left
      Ventricular Autothreshold (LVAT) features for AUTOGEN Cardiac Resynchronization Therapy
      Defibrillator (CRT-D) devices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the CAPTIVATE Clinical Study is to gather data to establish the safety and
      effectiveness of the PaceSafe Right Ventricular Autothreshold (RVAT) and Left Ventricular
      Autothreshold (LVAT) features to support the regulatory approval of the AUTOGEN CRT-D family
      of devices.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint is to Evaluate the System-related Complication-free Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Safety of the AUTOGEN was evaluated by the system-related complication-free rate (CFR) at 3-months post-implant. The system consists of the implanted AUTOGEN CRT-D pulse generator, RA lead (if implanted), RV lead, and LV lead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Accuracy of the RVAT Commanded Test Will be Evaluated by Comparing the RVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold.</measure>
    <time_frame>1-month and 3-month follow-up visits</time_frame>
    <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The RVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate commanded threshold is defined by: |commanded threshold - core lab determined threshold| ≤ 0.2 V; if the commanded threshold is ≤ 3.5V or |commanded threshold - core lab determined threshold| ≤ 0.5 V; if the commanded threshold is &gt; 3.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Accuracy of the LVAT Commanded Test Will be Evaluated by Comparing the LVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold.</measure>
    <time_frame>1-month and 3-month follow up visits</time_frame>
    <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The LVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate commanded threshold is defined by: commanded threshold - core lab determined threshold| ≤ 0.2 V; if the commanded threshold is ≤ 3.5V or |commanded threshold - core lab determined threshold| ≤ 0.5 V; if the commanded threshold is &gt; 3.5V. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Accuracy of the RVAT Ambulatory Test Will be Evaluated by Comparing the RVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold</measure>
    <time_frame>1-month and 3-month follow up visits</time_frame>
    <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits.The RVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate Ambulatory threshold is defined by:|Ambulatory threshold - ECG threshold| ≤ 0.6 V; if the ECG threshold is ≤ 3.5V or |Ambulatory threshold - ECG threshold| ≤ 1.0 V; if the ECG threshold is &gt; 3.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets form the 1-month and 3-month visits were pooled for purposes of endpoint analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Accuracy of the LVAT Ambulatory Test Will be Evaluated by Comparing the LVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold</measure>
    <time_frame>1-month and 3-month follow up visits</time_frame>
    <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The LVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate Ambulatory threshold is defined by: |Ambulatory threshold - ECG threshold| ≤ 1.0 V. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets form the 1-month and 3-month visits were pooled for purposes of endpoint analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RVAT Secondary Efficacy Endpoint: The Percent of RVAT Commanded Tests That Result in an Appropriate Outcome</measure>
    <time_frame>3-month follow up visit</time_frame>
    <description>This endpoint will evaluate the percent of RVAT commanded tests that result in an appropriate outcome. There are three possible outcomes to a commanded test:
A device-determined threshold
A threshold test code (indicating that a threshold could not be determined) representing an error condition that is beyond the control of the RVAT feature and could occur in the manual threshold tests
A threshold test code (indicating that a threshold could not be determined) that was due to a limitation of the RVAT feature and might not occur in manual threshold tests An appropriate RVAT outcome consists of the first two outcomes listed above: a device-determined threshold and a threshold test code representing an error condition that is beyond the control of the RVAT feature and could occur in the manual threshold tests. An inappropriate RVAT outcome consists of the last of the three outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVAT Secondary Efficacy Endpoint: The Percent of LVAT Commanded Tests That Result in an Appropriate Outcome</measure>
    <time_frame>3-month follow up visit</time_frame>
    <description>This endpoint will evaluate the percent of LVAT commanded tests that result in an appropriate outcome. There are three possible outcomes to a commanded test:
A device-determined threshold
A threshold test code (indicating that a threshold could not be determined) representing an error condition that is beyond the control of the LVAT feature and could occur in the manual threshold tests
A threshold test code (indicating that a threshold could not be determined) that was due to a limitation of the LVAT feature and might not occur in manual threshold tests An appropriate LVAT outcome consists of the first two outcomes listed above: a device-determined threshold and a threshold test code representing an error condition that is beyond the control of the LVAT feature and could occur in the manual threshold tests. An inappropriate LVAT outcome consists of the last of the three outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT-D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-D</intervention_name>
    <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
    <arm_group_label>CRT-D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects prescribed a CRT-D and indicated per guidelines, who will receive an AUTOGEN
             CRT-D model G160, G161, G172, G173

          2. Subjects who have an implanted functional endocardial right ventricular defibrillation
             lead or who will receive a endocardial right ventricular defibrillation lead

          3. Subjects who have an implanted functional bipolar or unipolar left ventricular lead or
             who will receive a bipolar or unipolar left ventricular lead

          4. Subjects who are willing and capable of providing informed consent to undergo a device
             implant procedure, and to participate in all testing and follow-ups defined in this
             protocol

          5. Subjects whose age is 18 or above, or of legal age to give informed consent specific
             to national law

        Exclusion Criteria:

          1. Subjects who have an implanted multipolar (&gt;2poles) left ventricular lead or who will
             receive a multipolar (&gt;2poles) left ventricular lead

          2. Subjects with an unknown model/manufacturer, or implant date for the RA, RV or LV lead

          3. Subjects for whom a RV defibrillation lead manufactured by St. Jude Medical or
             Biotronik is implanted, is planned to be implanted, or has been abandoned

          4. Implanted with an active Medtronic Sprint Fidelis® lead models: 6930, 6931, 6948 or
             6949

          5. Subjects with an implanted or abandoned St. Jude Medical QuickSite® or QuickFlex® lead
             models: 1056T, 1058T, 1156T, 1158T

          6. Subjects with a RV or LV lead revision or extraction within 30 days of enrollment

          7. Subjects with an implanted lead that is planned to be extracted during the study
             implant procedure

          8. Subjects with an active implanted RA or RV lead that is greater than 10 years old,
             unless the lead will be abandoned

          9. Subjects with an active implanted LV lead that is greater than 8 years old, unless the
             lead will be abandoned

         10. Subjects preexisting unipolar pacemaker that will not be explanted/abandoned

         11. Subjects with a life expectancy less than 6 months

         12. Subjects with a prosthetic mechanical tricuspid heart valve

         13. Women of childbearing age who are pregnant or plan to become pregnant. NOTE: women of
             childbearing potential with an uncertain pregnancy status must have a negative
             pregnancy test within 7 days prior to enrollment. Pregnancy tests are required as part
             of standard routing clinical practice at all centers whenever female patients are
             exposed to x-ray radiation. Since this protocol does not require any exposure of the
             female patients to x-ray and x-ray exposure is part of the clinical procedure, it is
             the responsibility of the investigators to ensure that pregnant females will not be
             exposed to x-ray at any time

         14. Subject enrolled in a concurrent study, except national/governmental registries that
             do not require a signed informed consent form, without the written approval from
             Boston Scientific

         15. Subjects who are not geographically stable, to the extent that it would prevent
             attending the study follow-ups at the investigational center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Ellenbogen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delray Medical Center</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Community Hospital</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winter Haven Hospital</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health LaPorte</name>
      <address>
        <city>LaPorte</city>
        <state>Indiana</state>
        <zip>46350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via-Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cardiovascular Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steward St. Elizabeth's Medical Center of Boston, Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Health System</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cox Health</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Health Center</name>
      <address>
        <city>Poland</city>
        <state>Ohio</state>
        <zip>44514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Lebanon</city>
        <state>Pennsylvania</state>
        <zip>17042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center-Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Clinic of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Southwest Medical</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <results_first_submitted>March 9, 2017</results_first_submitted>
  <results_first_submitted_qc>August 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2017</results_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Threshold algorithms</keyword>
  <keyword>CRT-D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CRT-D</title>
          <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="193">Active subjects at the end of 3 month follow up visit for primary end point data collection</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Total Withdrawals</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Attempt</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CRT-D</title>
          <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Races</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undisclosed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint is to Evaluate the System-related Complication-free Rate</title>
        <description>Safety of the AUTOGEN was evaluated by the system-related complication-free rate (CFR) at 3-months post-implant. The system consists of the implanted AUTOGEN CRT-D pulse generator, RA lead (if implanted), RV lead, and LV lead.</description>
        <time_frame>3 months</time_frame>
        <population>Implant + Attempt Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
            <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint is to Evaluate the System-related Complication-free Rate</title>
          <description>Safety of the AUTOGEN was evaluated by the system-related complication-free rate (CFR) at 3-months post-implant. The system consists of the implanted AUTOGEN CRT-D pulse generator, RA lead (if implanted), RV lead, and LV lead.</description>
          <population>Implant + Attempt Subjects</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="79.5">Only lower confidence interval limit was considered for end point result</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Accuracy of the RVAT Commanded Test Will be Evaluated by Comparing the RVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold.</title>
        <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The RVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate commanded threshold is defined by: |commanded threshold – core lab determined threshold| ≤ 0.2 V; if the commanded threshold is ≤ 3.5V or |commanded threshold – core lab determined threshold| ≤ 0.5 V; if the commanded threshold is &gt; 3.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis.</description>
        <time_frame>1-month and 3-month follow-up visits</time_frame>
        <population>A total of 288 paired datasets (from 171 unique subjects in whom RVAT threshold was available), each dataset consisting of a commanded RVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
            <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>The Accuracy of the RVAT Commanded Test Will be Evaluated by Comparing the RVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold.</title>
          <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The RVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate commanded threshold is defined by: |commanded threshold – core lab determined threshold| ≤ 0.2 V; if the commanded threshold is ≤ 3.5V or |commanded threshold – core lab determined threshold| ≤ 0.5 V; if the commanded threshold is &gt; 3.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis.</description>
          <population>A total of 288 paired datasets (from 171 unique subjects in whom RVAT threshold was available), each dataset consisting of a commanded RVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
          <units>percentage of commanded RVAT thresholds</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Commanded RVAT thresholds paired dataset</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Commanded RVAT thresholds paired dataset</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.9">Only lower confidence interval limit was considered for end point result</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Accuracy of the LVAT Commanded Test Will be Evaluated by Comparing the LVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold.</title>
        <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The LVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate commanded threshold is defined by: commanded threshold – core lab determined threshold| ≤ 0.2 V; if the commanded threshold is ≤ 3.5V or |commanded threshold – core lab determined threshold| ≤ 0.5 V; if the commanded threshold is &gt; 3.5V. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis.</description>
        <time_frame>1-month and 3-month follow up visits</time_frame>
        <population>A total of 324 paired datasets (from 182 unique subjects in whom LVAT threshold was available), each dataset consisting of a commanded LVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
            <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>The Accuracy of the LVAT Commanded Test Will be Evaluated by Comparing the LVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold.</title>
          <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The LVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate commanded threshold is defined by: commanded threshold – core lab determined threshold| ≤ 0.2 V; if the commanded threshold is ≤ 3.5V or |commanded threshold – core lab determined threshold| ≤ 0.5 V; if the commanded threshold is &gt; 3.5V. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis.</description>
          <population>A total of 324 paired datasets (from 182 unique subjects in whom LVAT threshold was available), each dataset consisting of a commanded LVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
          <units>Percentage of commanded LVAT thresholds</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Commanded LVAT thresholds-paired dataset</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Commanded LVAT thresholds-paired dataset</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="96.0">Only lower confidence interval limit was considered for end point result</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Accuracy of the RVAT Ambulatory Test Will be Evaluated by Comparing the RVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold</title>
        <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits.The RVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate Ambulatory threshold is defined by:|Ambulatory threshold – ECG threshold| ≤ 0.6 V; if the ECG threshold is ≤ 3.5V or |Ambulatory threshold – ECG threshold| ≤ 1.0 V; if the ECG threshold is &gt; 3.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets form the 1-month and 3-month visits were pooled for purposes of endpoint analysis.</description>
        <time_frame>1-month and 3-month follow up visits</time_frame>
        <population>A total of 314 paired datasets (from 183 unique subjects in whom RVAT threshold was available), each dataset consisting of an ambulatory RVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
            <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>The Accuracy of the RVAT Ambulatory Test Will be Evaluated by Comparing the RVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold</title>
          <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits.The RVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate Ambulatory threshold is defined by:|Ambulatory threshold – ECG threshold| ≤ 0.6 V; if the ECG threshold is ≤ 3.5V or |Ambulatory threshold – ECG threshold| ≤ 1.0 V; if the ECG threshold is &gt; 3.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets form the 1-month and 3-month visits were pooled for purposes of endpoint analysis.</description>
          <population>A total of 314 paired datasets (from 183 unique subjects in whom RVAT threshold was available), each dataset consisting of an ambulatory RVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
          <units>Percentage of RVAT ambulatory thresholds</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>RVAT ambulatory threshold paired dataset</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>RVAT ambulatory threshold paired dataset</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="97.5">Only lower confidence interval limit was considered for end point result</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Accuracy of the LVAT Ambulatory Test Will be Evaluated by Comparing the LVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold</title>
        <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The LVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate Ambulatory threshold is defined by: |Ambulatory threshold – ECG threshold| ≤ 1.0 V. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets form the 1-month and 3-month visits were pooled for purposes of endpoint analysis.</description>
        <time_frame>1-month and 3-month follow up visits</time_frame>
        <population>A total of 300 paired datasets (from 175 unique subjects in whom LVAT threshold was available), each dataset consisting of a ambulatory LVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
            <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>The Accuracy of the LVAT Ambulatory Test Will be Evaluated by Comparing the LVAT Determined Threshold to a Core Lab (Independent Physician) Determined Threshold</title>
          <description>Accuracy of the algorithm will be measured for all patients, by comparing algorithm determined threshold to a core lab determined threshold at both the 1-month and 3-month follow-up visits. The LVAT determined threshold for all patients at 1-month and 3-month follow-up visits are pooled for final analysis. An accurate Ambulatory threshold is defined by: |Ambulatory threshold – ECG threshold| ≤ 1.0 V. Paired datasets from the 1-month and 3-month visits were pooled for the purpose of this endpoint analysis. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets form the 1-month and 3-month visits were pooled for purposes of endpoint analysis.</description>
          <population>A total of 300 paired datasets (from 175 unique subjects in whom LVAT threshold was available), each dataset consisting of a ambulatory LVAT threshold and a core lab determined threshold, were collected at the 1-month and 3- month visits and pooled for final analysis.</population>
          <units>Percentage of accurate threshold</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>LVAT ambulatory threshold paired dataset</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>LVAT ambulatory threshold paired dataset</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="95.7">Only lower confidence interval limit was considered for end point result</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RVAT Secondary Efficacy Endpoint: The Percent of RVAT Commanded Tests That Result in an Appropriate Outcome</title>
        <description>This endpoint will evaluate the percent of RVAT commanded tests that result in an appropriate outcome. There are three possible outcomes to a commanded test:
A device-determined threshold
A threshold test code (indicating that a threshold could not be determined) representing an error condition that is beyond the control of the RVAT feature and could occur in the manual threshold tests
A threshold test code (indicating that a threshold could not be determined) that was due to a limitation of the RVAT feature and might not occur in manual threshold tests An appropriate RVAT outcome consists of the first two outcomes listed above: a device-determined threshold and a threshold test code representing an error condition that is beyond the control of the RVAT feature and could occur in the manual threshold tests. An inappropriate RVAT outcome consists of the last of the three outcomes listed above.</description>
        <time_frame>3-month follow up visit</time_frame>
        <population>A total of 157 unique subjects in whom a paired RVAT dataset was collected at the 3-month follow up visit. A paired dataset consisted of an RVAT threshold test outcome and core lab determined threshold test outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
            <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>RVAT Secondary Efficacy Endpoint: The Percent of RVAT Commanded Tests That Result in an Appropriate Outcome</title>
          <description>This endpoint will evaluate the percent of RVAT commanded tests that result in an appropriate outcome. There are three possible outcomes to a commanded test:
A device-determined threshold
A threshold test code (indicating that a threshold could not be determined) representing an error condition that is beyond the control of the RVAT feature and could occur in the manual threshold tests
A threshold test code (indicating that a threshold could not be determined) that was due to a limitation of the RVAT feature and might not occur in manual threshold tests An appropriate RVAT outcome consists of the first two outcomes listed above: a device-determined threshold and a threshold test code representing an error condition that is beyond the control of the RVAT feature and could occur in the manual threshold tests. An inappropriate RVAT outcome consists of the last of the three outcomes listed above.</description>
          <population>A total of 157 unique subjects in whom a paired RVAT dataset was collected at the 3-month follow up visit. A paired dataset consisted of an RVAT threshold test outcome and core lab determined threshold test outcome.</population>
          <units>percentage of appropriate outcome</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="79.9">Only lower confidence interval limit was considered for end point result</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVAT Secondary Efficacy Endpoint: The Percent of LVAT Commanded Tests That Result in an Appropriate Outcome</title>
        <description>This endpoint will evaluate the percent of LVAT commanded tests that result in an appropriate outcome. There are three possible outcomes to a commanded test:
A device-determined threshold
A threshold test code (indicating that a threshold could not be determined) representing an error condition that is beyond the control of the LVAT feature and could occur in the manual threshold tests
A threshold test code (indicating that a threshold could not be determined) that was due to a limitation of the LVAT feature and might not occur in manual threshold tests An appropriate LVAT outcome consists of the first two outcomes listed above: a device-determined threshold and a threshold test code representing an error condition that is beyond the control of the LVAT feature and could occur in the manual threshold tests. An inappropriate LVAT outcome consists of the last of the three outcomes listed above.</description>
        <time_frame>3-month follow up visit</time_frame>
        <population>A total of 182 unique subjects in whom a paired LVAT dataset was collected at the 3-month follow up visit. A paired dataset consisted of an LVAT threshold test outcome and core lab determined threshold test outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>CRT-D</title>
            <description>For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated</description>
          </group>
        </group_list>
        <measure>
          <title>LVAT Secondary Efficacy Endpoint: The Percent of LVAT Commanded Tests That Result in an Appropriate Outcome</title>
          <description>This endpoint will evaluate the percent of LVAT commanded tests that result in an appropriate outcome. There are three possible outcomes to a commanded test:
A device-determined threshold
A threshold test code (indicating that a threshold could not be determined) representing an error condition that is beyond the control of the LVAT feature and could occur in the manual threshold tests
A threshold test code (indicating that a threshold could not be determined) that was due to a limitation of the LVAT feature and might not occur in manual threshold tests An appropriate LVAT outcome consists of the first two outcomes listed above: a device-determined threshold and a threshold test code representing an error condition that is beyond the control of the LVAT feature and could occur in the manual threshold tests. An inappropriate LVAT outcome consists of the last of the three outcomes listed above.</description>
          <population>A total of 182 unique subjects in whom a paired LVAT dataset was collected at the 3-month follow up visit. A paired dataset consisted of an LVAT threshold test outcome and core lab determined threshold test outcome.</population>
          <units>percentage of appropriate outcome</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="91.5">Only lower confidence interval limit was considered for end point result</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events reported were collected from ICF signature until the last study follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CRT-D</title>
          <description>CRT-D: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated.
Subjects in whom AUTOGEN CRT-D was successfully implanted or an attempt to implant made were considered to be at risk for adverse events. There were a total of 210 implants and attempts.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Laboratory Values</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Reaction - Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arterial/Venous Trombolytic Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation (Af)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial Tachyarrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Chest Pain - Ischemic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Chest Pain - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Coronary Venous Perforation Without Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment - Elevated Threshold - Rv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment - Extracardiac Stimulation - Lv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment - Multiple Signs - Rv</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment - No Reported Signs - Lv</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment - No Reported Signs - Ra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment - Unable To Capture - Lv</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment - Unable To Capture - Ra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dyspnea - Heart Failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Elevated Threshold - Lv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Extracardiac Stimulation - Lv</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Heart Failure Symptoms - Unspecified</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypotension - Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Impedance &lt; 300 Ohms - Ra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Inadvertent Vt/Vf</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Inappropriate Tachy Therapy - Svt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Intracardiac Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Mitral Regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Multi-System Failure - Heart Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Multiple Heart Failure Symptoms</sub_title>
                <counts group_id="E1" events="34" subjects_affected="25" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Myocardial Perforation Post-Implant - Rv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Myocardial Perforation With Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Other-Lead-Procedure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Peripheral Edema - Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Premature Ventricular Contractions (Pvc)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Unable To Capture - Lv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Unable To Convert - Defibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation (Vf)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ventricular Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia (Vt)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Failure To Implant Epicardial Lv Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Inability To Place The Lv Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Left Chest Wall Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>ICD shocks</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Unable To Insert Lv Lead With Initial Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Vestibulitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Patient Death - unknown cause</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-System Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Multiple Symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (&gt; 3 Days Post-Implant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Systemic Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Severe Rt. Leg Stump Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Physical Trauma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Renal Failure Due To Contrast Media - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Renal Insufficiency - Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Reaction - Respiratory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Copd Exacerbation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema - Heart Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hematoma - Pocket (&lt;=30 Days Post-Implant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Post-Surgical Wound Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident (Cva)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Left Leg Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial Tachyarrhythmias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Unable to perform Threshold test-RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Chest Pain-Ischemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Chest Pain-Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Coronary Venous Dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment-extracardiac stimulation-RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment-LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment-unable to capture-LV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dislodgment-unable to capture-RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dyspnea-heart failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation-LV</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Insulation breach-RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Mitral regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Multiple Heart Failure Symptoms</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nonsustained Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Other PG-system-procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cardiovascular event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Oversensing-RV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pacemaker Mediated Tachycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Peripheral edema-heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>PG system-event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Thromboembolic events</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Unable to capture-LV lead</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Undersensing-RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ventricular Tacchyarrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>ICD shocks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Low LVEF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>High LV lead impedance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>High RV lead impedance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Low pacing output</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual disturbances</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Laboratory Values</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cocaine Abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post surgical infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Physical Trauma</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Psychological effect due to device therapy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitorurinary</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hematoma (less than 30 days post implant)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Integumentary</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Post-surgical Pocket Hemorhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Swollen neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Venous Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The RVAT and LVAT endpoints are compared against a performance goal rather than to a randomized control arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gregory Voss</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>6515813068</phone>
      <email>Gregory.Voss@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

